T-ALL

Gracell Biotechnologies Announces Details of Poster Presentation at AACR Annual Meeting 2022

Retrieved on: 
화요일, 3월 8, 2022
Online, NASDAQ, Industry, CD19, AACR, Graft-versus-host disease, American Association for Cancer Research, Form 20-F, SMART, Annual report, Private Securities Litigation Reform Act, Holm–Bonferroni method, U.S. Securities and Exchange Commission, Acute lymphoblastic leukemia, Lymphoid leukemia, T-ALL, CD7, Cancer, B-ALL, HLA, IIT, CAR, Bone marrow, Risk, Lymphatic system, Patient, Security (finance), American Association, ALL, HVG, Gene editing, PALO, Association, Poster, Lymphocyte, LinkedIn, Vaccine, Pharmaceutical industry, Graceling

PALO ALTO, Calif. and SUZHOU, China, March 8, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the details of its poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022, being held from April 8-13 in New Orleans, Louisiana.

Key Points: 
  • GC502 is currently being studied in an open-label single-arm Phase 1 IIT in China for patients with B-ALL.
  • Details of the presentation are as follows:
    The full text of the abstract will be published to the AACR Online Itinerary Planner at 1:00PM ET on Friday, April 8.
  • The e-poster will be viewable to registered attendees on the AACR's e-poster website from Friday, April 8, through Wednesday, July 13.
  • Gracell Biotechnologies Inc.("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies.

Gracell Biotechnologies Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform

Retrieved on: 
화요일, 2월 22, 2022
Online, CD7, Holm–Bonferroni method, PALO, Relapse, B-ALL, NK, CD19, IIT, NASDAQ, Immune system, ALL, CAR, Company, Lymphocyte, T-ALL, Acute lymphoblastic leukemia, Safety, American Association for Cancer Research, Bone marrow, American Association, HVG, Trial of the century, Lymphatic system, Cancer, AACR, Haematopoietic system, Graceling, Lymphoid leukemia, HLA, Patient, Survival, Association, Vaccine

GC502 is an allogeneic CD19/CD7 dual-directed chimeric antigen receptor (CAR) T cell therapy currently under development for multiple indications including B-ALL.

Key Points: 
  • GC502 is an allogeneic CD19/CD7 dual-directed chimeric antigen receptor (CAR) T cell therapy currently under development for multiple indications including B-ALL.
  • Another lead product candidate of the TruUCAR platform is GC027, an allogeneic CAR-T therapy targeting CD7 for the treatment of adults with T-cell lymphoblastic leukemia (T-ALL).
  • Both GC502 and GC027 are poised to strengthen the allogeneic platform approach of TruUCAR.
  • "With our TruUCAR platform, Gracell aims to address multiple challenges associated with autologous CAR-T products including availability, speed to therapy and cost.

Genetic ancestry provides important context for understanding global diversity in childhood leukemia

Retrieved on: 
목요일, 1월 27, 2022
St. Jude Children's Research Hospital, Biology, UCSF Benioff Children's Hospital, Genetic variation, ALSAC, JAMA Oncology, Cancer, CRLF2, Patient, Philadelphia, DUX4, University, KK Women's and Children's Hospital, National, Andijan State Medical Institute, University of California, National Cancer Institute, Child, T-ALL, Acute lymphoblastic leukemia, Social media, Department, Leukemia, Research, ALL, Multimedia, NCI-designated Cancer Center, Survival, Children's Hospital of Philadelphia, Prognosis, Risk, Incidence, Yang, NUDT15, Toxicity, Awareness, Hospital, University Malaya Medical Centre, Medicine, Vaccine, Pharmacy, Native, Jude the Apostle

The scientists assembled an international cohort to determine how genetic ancestry affects leukemia biology and outcomes for modern therapy.

Key Points: 
  • The scientists assembled an international cohort to determine how genetic ancestry affects leukemia biology and outcomes for modern therapy.
  • Racial disparities exist in both the incidence and treatment outcomes for childhood ALL, and there is limited data on the genetic basis for such disparities.
  • The researchers used a genomic technique called RNA-sequencing to comprehensively characterize ALL molecular subtype and genetic ancestry of each child.
  • These NUDT15 variants are rarely found in children with European ancestry, highlighting how important findings can be missed if studies do not include diversity in genetic ancestry.

Beam Therapeutics Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones

Retrieved on: 
일요일, 1월 9, 2022
HSC, Safety, COVID-19, Sickle cell disease, Liver, Food, HBA, Gene editing, T-ALL, Patient, LNP, IND, DNA, Stem cell, HBS, LNP Media Group, Thalassemia, Conference, U.S. Securities and Exchange Commission, Annual report, Security (finance), Polymerization, Private Securities Litigation Reform Act, Tissue, Disease, Food and Drug Administration, SCD, Health, Patent, GLOBE, Technology, Fetal hemoglobin, Nasdaq, Biotechnology, Oil, Vaccine, Pharmaceutical industry, Lumber, Beam

CAMBRIDGE, Mass., Jan. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today outlined anticipated 2022 milestones across its ex vivo programs targeting editing of hematopoietic stem cells (HSCs) and T cells and in vivo programs targeting editing of liver cells leveraging lipid nanoparticles (LNPs) for delivery. Updates include that the company has selected its fourth development candidate and first in vivo base editing candidate, BEAM-301, which aims to correct the R83C mutation for the potential treatment of patients with glycogen storage disorder Ia (GSDIa).

Key Points: 
  • ET
    CAMBRIDGE, Mass., Jan. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today outlined anticipated 2022 milestones across its ex vivo programs targeting editing of hematopoietic stem cells (HSCs) and T cells and in vivo programs targeting editing of liver cells leveraging lipid nanoparticles (LNPs) for delivery.
  • We made significant progress across our base editing portfolio in 2021, which culminated in U.S. Food and Drug Administration clearance of the first investigational new drug application of a base editing therapeutic, BEAM-101.
  • Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines.
  • This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs.

Ayala Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

Retrieved on: 
목요일, 1월 6, 2022
Pivotal, Novartis, Therapy, AYLA, T-ALL, Patient, T-Cell Acute Lymphoblastic Leukemia, MM, Cancer, Multiple myeloma, TNBC, Conference, Neoplasm, ACC, Adenoid cystic carcinoma, FDA, GLOBE, Nasdaq, Plantar fibromatosis, Pharmaceutical industry, Notch

REHOVOT, Israel and WILMINGTON, Del., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will present at the H.C. Wainwright BioConnect Virtual Conference, taking place on January 10-13, 2022.

Key Points: 
  • REHOVOT, Israel and WILMINGTON, Del., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will present at the H.C. Wainwright BioConnect Virtual Conference, taking place on January 10-13, 2022.
  • A webcast of the presentation will be available on the Events and Presentations section of the Ayala Pharmaceuticals website, beginning at 7:00 AM ET on Monday, January 10, 2022.
  • Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations.
  • Ayalas approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations.

OSE Immunotherapeutics Presents First Preclinical Efficacy Data on Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia

Retrieved on: 
월요일, 12월 13, 2021
Biomarker, Interleukin 7, Severe acute respiratory syndrome coronavirus 2, T-cell acute lymphoblastic leukemia, University of Kiel, Prognosis, BCP, Degenerative disease, OSE, PD-1, Veloxis Pharmaceuticals, Fortification, Cancer, Nivolumab, ISIN, Vaccination, B cell, CD127, T-ALL, Mab, Inflammation, Immunotherapy, Schleswig-Holstein, Safety, Boehringer Ingelheim, GLOBE, ASH, Cytokine release syndrome, Partnership, Society, Autoimmune disease, COVID-19, CD19, Research, Tissue, Mnemos EP, Macrophage, Pancreatic cancer, Large-cell lung carcinoma, Poster, University Medical Center Schleswig Holstein, Lymphocytopenia, IL-7, Patient, Ulcerative colitis, Department, University Medical Center, Immune system, Acute lymphoblastic leukemia, Epitope, University, Pharmaceutical industry, Vaccine, Diagnosis, PDX

OSE-127 is a monoclonal immunomodulatory antibody targeting the CD127 receptor, the alpha chain of the interleukin-7 receptor (IL-7R) that induces a powerful antagonist effect on effector T lymphocytes.

Key Points: 
  • OSE-127 is a monoclonal immunomodulatory antibody targeting the CD127 receptor, the alpha chain of the interleukin-7 receptor (IL-7R) that induces a powerful antagonist effect on effector T lymphocytes.
  • Despite the favourable prognosis of BCP-ALL, relapse remains a clinical challenge and novel targeted immunotherapy options are urgently needed.
  • OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.
  • OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.

Wugen Presents New Preclinical Data Supporting the Safety and Efficacy of WU-CART-007 for T-Cell Malignancies at the 63rd Annual Society of Hematology (ASH) Annual Meeting

Retrieved on: 
일요일, 12월 12, 2021
Professional Services, Health, Other Science, Finance, General Health, Research, Science, Food, NK, CRISPR, FDA, Acute leukemia, Poster, AML, Lymphatic system, LBL, Graft-versus-host disease, T-cell acute lymphoblastic leukemia, NCT, IND, T-ALL, TRAC, Phenotype, Risk, Safety, Patient, Mortality, Infection, Program, CD7, Technology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Vaccine, Pharmaceutical industry

Further, todays data highlighted Wugens clinical readiness and robust manufacturing process for WU-CART-007.

Key Points: 
  • Further, todays data highlighted Wugens clinical readiness and robust manufacturing process for WU-CART-007.
  • WU-CART-007 is an off-the-shelf, fratricide-resistant CD7-targeted CAR-T cell therapy designed to overcome the technological challenges of harnessing CAR-T cells to treat CD7+ hematological malignancies.
  • Wugen is deploying CRISPR/Cas9 gene editing technology to delete CD7 and the T-cell receptor alpha constant (TRAC), preventing CAR-T cell fratricide and mitigating the risk of graft-versus-host-disease (GvHD).
  • Adult and pediatric patients with T-cell malignancies experience high rates of relapse and mortality, said Dan Kemp, Ph.D., President and Chief Executive Officer of Wugen.

Ayala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
월요일, 11월 15, 2021
BCMA, Safety, Cancer, T-Cell Acute Lymphoblastic Leukemia, T-ALL, Partial, TNBC, European Society for Medical Oncology, Novartis, Clinical trial, Plantar fibromatosis, Area studies, ACC, D, MM, Treatment, ESMO, Gene expression, Adenoid cystic carcinoma, Temple of Israel (Wilmington, North Carolina), Doctor of Philosophy, Patient, Neoplasm, Company, Research, GLOBE, Therapy, Ongo, PDX, Multiple myeloma, Pivotal, Oncology, Nasdaq, AYLA, FDA, Current, Adult, Pharmaceutical industry

Recent Business Highlights and Upcoming Milestones:

Key Points: 
  • Recent Business Highlights and Upcoming Milestones:
    Published Two Case Studies Highlighting Clinical Activity of AL101 in Desmoid Tumors in Current Oncology: In September 2021, Ayala published two case studies of adult patients with desmoid tumors treated with AL101.
  • Collaboration Revenue: Collaboration revenue was $0.6 million for the third quarter of 2021, as compared to $0.7 million for the same period in 2020.
  • G&A Expenses: General and administrative expenses were $2.2million for the third quarter of 2021, compared to $1.9 million for the same period in 2020.
  • Net Loss: Net loss was $9.8million for the third quarter of 2021, resulting in a basic and diluted net loss per share of $0.68.

Beam Therapeutics Reports Preclinical Data Highlighting Multiplex Base Editing Approach to Create Anti-CD5 CAR T-cell Investigational Therapies for T-Cell Malignancies

Retrieved on: 
금요일, 11월 12, 2021
CD5, Efficiency, Safety, SITC, Chromosomal translocation, T-ALL, Private Securities Litigation Reform Act, Therapy, T-cell lymphoma, Neoplasm, Security (finance), Gene, Mouse, Technology, Society, COVID-19, CAR, Annual report, Biotechnology, Annual general meeting, U.S. Securities and Exchange Commission, GLOBE, Immunotherapy, DNA, Poster, Nasdaq, Patient, Immunosuppression, Gene editing, Patent, Multiplexing, Vaccine

Beam has developed a process using base editing to simultaneously silence five target genes, including CD5 and PD1, to create allogeneic anti-CD5 CAR T-cells with enhanced effector function for potential use as off-the-shelf treatments for T-cell malignancies.

Key Points: 
  • Beam has developed a process using base editing to simultaneously silence five target genes, including CD5 and PD1, to create allogeneic anti-CD5 CAR T-cells with enhanced effector function for potential use as off-the-shelf treatments for T-cell malignancies.
  • We believe our approach using multiplexediting ofT-cells to produce allogeneic anti-CD5 CAR T investigational therapies may offer enhanced potency and more durable responses for patients with T-cell malignancies.
  • Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines.
  • This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs.

Wugen Presents New Preclinical Data from Novel Memory Natural Killer (NK) Platform at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

Retrieved on: 
금요일, 11월 12, 2021
Other Health, Research, General Health, Professional Services, Pharmaceutical, Oncology, Clinical Trials, Science, Biotechnology, Finance, Other Science, Health, GMP, SITC, AML, Cancer, Abstract (summary), Acute leukemia, T-ALL, LBL, Fibroblast, Infection, Acute myeloid leukemia, Society, NK, T-cell acute lymphoblastic leukemia, CD16, Phenotype, ADCC, Immunotherapy, Memory, Vaccine

Wugen, Inc. , a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today presented new data from its best-in-class memory natural killer (NK) cell therapy platform at the Society for Immunotherapy of Cancers (SITC) 36th Annual Meeting.

Key Points: 
  • Wugen, Inc. , a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today presented new data from its best-in-class memory natural killer (NK) cell therapy platform at the Society for Immunotherapy of Cancers (SITC) 36th Annual Meeting.
  • The findings presented at SITC support development of WU-NK-101 as an off-the-shelf therapy for r/r AML and solid tumor indications.
  • These data showcase our differentiated approach to off-the-shelf cell therapies for cancer, said Dan Kemp, Ph.D., President and Chief Executive Officer of Wugen.
  • Todays presentation highlighted the following:
    WU-NK-101 memory NK cells demonstrated robust cytotoxic efficacy in vitro, producing high levels of immune-activating cytokines and immune-attracting chemokines.